Global beauty giant L’Oréal has increased its stake in Swiss dermatology company Galderma to 20%, underscoring its ambition to expand aggressively in the fast-growing aesthetics and dermatological skincare segment. 

The move builds on L’Oréal’s earlier minority investment in Galderma, which specializes in injectables, fillers, and advanced dermatology solutions. By boosting its shareholding, L’Oréal signals confidence in the booming global aesthetics market, projected to grow at double-digit rates over the next five years. 

Galderma, headquartered in Switzerland, is recognized as a leader in medical-grade skincare and aesthetic treatments, with a portfolio spanning Restylane fillers, Dysport neuromodulators, and Cetaphil skincare. The expanded partnership is expected to accelerate innovation and broaden access to professional beauty solutions worldwide. 

Industry analysts note that the deal positions L’Oréal to bridge consumer beauty with medical aesthetics, strengthening its footprint in a category increasingly sought after by Gen Z and millennial consumers. 

L’Oréal’s increased stake in Galderma marks a strategic bet on aesthetics as the next frontier of beauty growth.